🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Azacitidine

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome

    phase 2 small molecule completed

    1 trial

  2. Azacitidine (AZA) with Ruxolitinib

    The First People's Hospital of Lianyungang

    MDS/MPN

    phase 2 small molecule active

    1 trial

  3. Azacitidine Injection

    The First People's Hospital of Lianyungang

    B Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  4. Azacitidine in Combination With Venetoclax

    The First People's Hospital of Lianyungang

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  5. Azeliragon

    vTv Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  6. B-CIT and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  7. B-MAD chemotherapy

    Takeda

    Extranodal NK/T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  8. B10 L-BPA Injection

    Heron Therapeutics

    Meningioma

    phase 2 small molecule completed

    1 trial

  9. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  10. BAY 73-4506, AVELUMAB

    The George Institute

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  11. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  12. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  13. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  14. BCX17725

    Lacuna Pharma Pty Ltd

    Netherton Syndrome

    phase 2 small molecule active

    1 trial

  15. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  16. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  17. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  19. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

  20. BEAM-101

    Beam Therapeutics

    Sickle Cell Disease

    phase 2 mab active

    1 trial

  21. BEAM-201

    Beam Therapeutics

    Lymphoblastic Lymphoma

    phase 2 mab active

    1 trial

  22. BEAM-301: Single dose of BEAM-301 administered by IV

    Beam Therapeutics

    Glycogen Storage Disease Type Ia

    phase 2 small molecule active

    1 trial

  23. BEAM-302

    Beam Therapeutics

    Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

    phase 2 small molecule active

    1 trial

  24. BEAM-302

    Beam Therapeutics

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources